US cancer institute cancels nanotech research centers

first_img By Robert F. ServiceMay. 17, 2019 , 2:40 PM U.S. cancer institute cancels nanotech research centers Nanotechnology also has a unique place in cancer research, where making advances requires multiple disciplines, including chemistry, physics, cell biology, and patient care, to design novel drugs and drug carriers that can navigate the body and seek out and destroy tumors. “We’re talking about a different beast here,” says Michelle Bradbury, a radiologist at Memorial Sloan Kettering Cancer Center in New York City, who co-directs the Sloan Kettering-Cornell University CCNE. “The center format is perfect for that.” NCI launched eight CCNEs in 2005 for an initial 5-year term. Nine received funding in 2010 for the project’s second phase, and six in 2015 for phase three. In total, CCNEs received about $330 million over 15 years, Grodzinski says, with an additional $70 million in funding for training and other types of nanotechnology research centers. That, he says, represents between 10% to 20% of NCI’s funding for nanotechnology research, depending on the specific 5-year phase. NCI will continue to support nanotechnology through R01 and other grant mechanisms, Grodzinski says. But Bradbury and others are concerned that a more piecemeal funding approach might be less successful. “You might not see the integration between disciplines,” she says. Sign up for our daily newsletter Get more great content like this delivered right to you! Country Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe The U.S. National Cancer Institute (NCI) in Bethesda, Maryland, will halt funding next year for its long-running Centers of Cancer Nanotechnology Excellence (CCNEs), which are focused on steering advances in nanotechnology to detect and treat cancer. The shift marks nanotechnology’s “natural transition” from an emerging field requiring dedicated support to a more mature enterprise able to compete head to head with other types of cancer research, says Piotr Grodzinski, who heads NCI’s Nanodelivery Systems and Devices Branch, which oversees the CCNEs. “This doesn’t mean NCI’s interest in nanotechnology is decreasing.”Nevertheless, cancer nanotechnology experts see the decision as a blow. “It’s disappointing and very shortsighted given the emergence of nanotechnology and medicine,” says Chad Mirkin, who directs a CCNE at Northwestern University in Evanston, Illinois. CCNEs have spawned dozens of clinical trials for new drugs and drug delivery devices, as well as novel technologies for diagnosing disease, he says. “Cancer research needs new ways of making new types of medicines. Nanotechnology represents a way to do that,” he says. Email Click to view the privacy policy. Required fields are indicated by an asterisk (*)last_img

Leave a Reply

Your email address will not be published. Required fields are marked *